Vertex Pharmaceuticals Confident in Emerging Renal Franchise, Oppenheimer Says

MT Newswires Live05-06

Vertex Pharmaceuticals' (VRTX) management remains confident in its emerging renal franchise, suggesting it could rival or even exceed its cystic fibrosis franchise eventually, Oppenheimer said in a Tuesday note.

The strong uptake of Alyftrek is encouraging, and Oppenheimer expects continued growth in US and international markets, driven by adoption among treatment-naive patients, those who previously discontinued cystic fibrosis therapy, and patients who switched to Alyftrek, according to the note.

Uptake of Alyftrek among younger patients and more access in Europe should support long-term growth, according to the note. For Journavx, management remains confident in tripling total scripts in 2026, the brokerage said.

Management remains confident in Pove's profile, and the recent submission completion for Pove suggests a potential FDA decision by year-end, according to the note.

Oppenheimer said Inaxaplin represents the next key catalyst, with the phase 2 AMPLIFIED study readout now expected in H2, compared with the prior mid-2026 guidance.

Oppenheimer maintained an outperform rating on Vertex Pharmaceuticals with a price target of $600.

Price: 423.92, Change: -5.93, Percent Change: -1.38

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment